Role of biomarkers in chemotherapy-induced cardiotoxicity

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 121-129

  Cardinale Daniela, D ^a   Sandri, Maria Teresa ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Biomarkers; Cardiotoxicity; Chemotherapy; Natriuretic peptides; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; LISINOPRIL; MITOXANTRONE; MONOCLONAL ANTIBODY; NATRIURETIC FACTOR; PLACEBO; RAZOXANE; TRASTUZUMAB; TROPONIN; TROPONIN I; TROPONIN T; VALSARTAN;

ACUTE HEART INFARCTION; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MEGADOSE; EARLY DIAGNOSIS; EARLY INTERVENTION; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PATIENT MONITORING; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOLID TUMOR; BLOOD; CHEMICALLY INDUCED; HEART DISEASES; NEOPLASMS; PREDICTIVE VALUE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDES; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TROPONIN; UP-REGULATION;

EID: 77955907895     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.04.002     Document Type: Article

References (72)

1. Herbst R.S., Bajorin D.F., Bleiberg H., et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 2006, 24:190-205.
2. Yeh E.T.H., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis and management. Circulation 2004, 109:3122-3131.
3. Barry E., Alvarez J.A., Scully R.E., et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8:1039-1058.
4. Jones R.L., Ewer M.S. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006, 6:1229-1249.
5. Cheitlin M.D., Armstrong W.F., Aurigemma G.P., et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003, 108:1146-1162.
6. Steinherz L.J., Graham T., Hurwitz R., et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992, 89:942-949.
7. Meinardi M.T., Van der Graaf W.T.A., Van Veldhuisen D.J., et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999, 25:237-247.
8. Sabel M.S., Levine E.G., Hurd T., et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy?. Am J Clin Oncol 2001, 24:425-428.
9. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010, 55:213-220.
10. Healey Bird B.R.J., Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14:14-24.
11. Nielsen D., Jensen J.B., Dombernowsky P., et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990, 8:1806-1810.
12. Jensen B.V., Skovsgaard T., Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699-709.
13. Alpert J.S., Thygesen K., Antman E., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36:959-969.
14. O'Brien P.J. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008, 245:206-218.
15. Seino Y., Tomita Y., Nagai Y., et al. Cardioprotective effects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneous hypertensive rats. Circulation 1993, 88:I-633. [abstract].
16. Herman E.H., Zhang J., Lipshultz S.E., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237-2243.
17. Adamcová M., Simunek T., Kaiserová H., et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 2007, 237:218-228.
18. Simunek T., Klimtova I., Adamcova M., et al. Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemother Pharmacol 2003, 52:431-434.
19. Lipshultz S.E., Rifai N., Sallan S.E., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641-2648.
20. Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517-522.
21. Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13:710-715.
22. Sandri M.T., Cardinale D., Zorzino L., et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003, 49:248-252.
23. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
24. Auner H.W., Tinchon C., Linkesch W., et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003, 82:218-222.
25. Specchia G., Buquicchio C., Pansini N., et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005, 145:212-220.
26. Kilickap S., Barista I., Akgul E., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005, 16:798-804.
27. Cipolla C.M., Colombo A., Torrisi R., et al. Clinical and prognostic implications of early troponin I increase in trastuzumab induced cardiotoxicity 2010.
28. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
29. Dolci A., Dominici R., Cardinale D., et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008, 130:688-695. [Review].
30. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350:1349-1353.
31. Suzuki T., Hayashi D., Yamazaki T., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136:362-363.
32. Nousiainen T., Jantunen E., Vanninen E., et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol 1998, 61:347-353.
33. Hayakawa H., Komada Y., Hirayama M., et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001, 37:4-9.
34. Meinardi M.T., Van Veldhuisen D.J., Gietema J.A., et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001, 19:2746-2753.
35. Nousiainen T., Vanninen E., Jantunen E., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002, 251:228-234.
36. Poutanen T., Tikanoja T., Riikonen P., et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003, 21:2349-2356.
37. Daugaard G., Lassen U., Bie P., et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005, 7:87-93.
38. Sandri M.T., Salvatici M., Cardinale D., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem 2005, 51:1405-1410.
39. Pinarli F.G., Oǧuz A., Tunaoǧlu F.S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005, 44:370-377.
40. Nakamae H., Tsumura K., Terada Y., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005, 104:2492-2498.
41. Pichon M.F., Cvitkovic F., Hacene K., et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005, 19:567-576.
42. Soker M., Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005, 26:1197-1202.
43. Erkus B., Demirtas S., Yarpuzlu A.A., et al. Early prediction of anthracycline induced cardiotoxicity. Acta Pedriatr 2007, 96:506-509.
44. Aggarwal S., Pettersen M.D., Bhambhani K., et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007, 49:812-816.
45. Ekstein S., Nir A., Rein A.J., et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007, 29:440-444.
46. Zver S., Zadnik V., Bunc M., et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008, 88:227-236.
47. Knobloch K., Tepe J., Lichtinghagen R., et al. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol 2008, 125:113-115.
48. Horacek J.M., Pudil R., Jebavy L., et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007, 29:309-313.
49. Dodos F., Halbsguth T., Erdmann E., et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008, 97:318-326.
50. Broeyer F.J., Osanto S., Ritsema van Eck H.J., et al. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol 2008, 134:961-968.
51. Mavinkurve-Groothuis A.M., Groot-Loonen J., Bellersen L., et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 2009, 52:631-636.
52. Cil T., Kaplan A.M., Altintas A., et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig 2009, 29:131-137.
53. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004, 50:33-50.
54. Vittorini S., Prontera C., Zucchelli G.C., et al. Cardiac natriuretic hormones: methodological aspects. Immuno-Analyse Biol Spec 2007, 22:209-272.
55. Vittorini S., Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiologypractice. Clin Chem Lab Med 2008, 6:748-763.
56. ElGhandour A.H., El Sorady M., Azab S., et al. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rev 2009, e6:1.
57. Horacek J.M., Tichy M., Pudil R., et al. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann Oncol 2008, 19:1656-1657.
58. Mercuro G., Cadeddu C., Piras A., et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007, 12:1124-1133.
59. Nuver J., Smit A.J., Sleijfer D.T., et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004, 40:701-706.
60. Vaughn D.J., Palmer S.C., Carver J.A., et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008, 112:1949-1953.
61. Altena R., Perik P., van Veldhuisen D.J., et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009, 10:391-399. [Review].
62. Wouters K.A., Kremer L.C.M., Miller T.L., et al. Protecting against anthracyclines-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578.
63. Okumura K., Jin D., Takai S., et al. Beneficial effects of angiotensin-converting enzyme inhibition in adryamicin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002, 88:183-188.
64. Tokudome T., Mizushige K., Noma T., et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000, 36:361-368.
65. Vaynblat M., Shah H.R., Bhaskaran D., et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002, 4:583-586.
66. Sacco G., Bigioni M., Evangelista S., et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001, 414:71-78.
67. Abd El-Aziz M.A., Othman A.I., Amer M., et al. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001, 21:469-473.
68. Maeda A., Honda M., Kuramochi T., et al. An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol 1997, 24:720-726.
69. Toko H., Oka T., Zou Y., et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002, 25:597-603.
70. Spallarossa P., Garibaldi S., Altieri P., et al. Carvedilol prevents doxorubicin-induced free radicals release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004, 37:837-846.
71. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracyclines-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258-2262.
72. Youssef G., Links M. The prevention and management of cardiovascular complication of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005, 5:233-243.